Cypress Bioscience Articles

Cypress Bioscience finally succumbs to Ramius advances, but at $6.50/share in cash

16 December 2010

Cypress Biosciences turns down $6 per share raised offer from Ramius

15 December 2010

Ramius increases unsolicited offer for Cypress Biosciences to $5.50 a share

13 December 2010

Cypress Bioscience goes on a spending spree, gaining rights to autism product and Staccato nicotine technology

27 August 2010

Ramius makes unsolicited, 60% premium offer to buy Cypress Bioscience for $4.00 per share in cash

20 July 2010

Cypress Bioscience in-licenses novel antipsychotic from BioLineRx for potential $365 million

21 June 2010

Showing 1-6 of 6 articles

Go to beginning

Previous

1

Next

Go to end